Current and New Novel Combination Treatments for Metastatic Triple-Negative Breast Cancer.

Curr Oncol · 2022 · PMC9323790 · PMID 35877237

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

Another phase I/IIB trial showed a trend toward better CBR among AR-positive metastatic TNBC patients when treated with a combination of taselisib (PI3K inhibitor) plus enzalutamide [ 59 ].

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.